01Neurocrine Biosciences reported Q3 2026 EPS of $3.29, beating consensus estimates by $0.70 per share, with revenue of $1.1B versus estimated $1.0B.
02The company's 27% earnings beat represents a significant outperformance that may trigger analyst estimate revisions and influence institutional positioning.
03Neurocrine has beaten earnings estimates for three consecutive quarters, with surprise magnitudes of 35.7%, 27.0%, and 20.5% in Q2, Q3, and Q1 respectively.
04The stock trades at $164.85 with a market capitalization of $15.4B as of the earnings release date.
Earnings Results
Neurocrine Biosciences (NASDAQ:NBIX) reported quarterly earnings results on November 02, 2026 that exceeded analyst expectations.
The Healthcare company reported earnings per share of $3.29, beating the consensus estimate of $2.59 by $0.70 per share. Revenue came in at $1.1B, beating the estimate of $1.0B.
Company Overview
Neurocrine Biosciences's stock moved following the earnings release. The stock currently trades at $164.85 with a market capitalization of $15.4B.
Neurocrine Biosciences's earnings outperformance reflects execution that exceeded Wall Street's expectations. Earnings beats can lead to upward estimate revisions from analysts, which often correlate with sustained stock price appreciation over the following weeks as models are updated.
The 27% beat relative to consensus estimates is a notable deviation. Earnings surprises of this magnitude often trigger analyst revisions and can influence institutional positioning in the weeks following the report.
Earnings reports are most useful when viewed as part of a trend rather than in isolation. Investors tracking Neurocrine Biosciences should compare this quarter's results against both year-over-year figures and sequential performance to identify whether the business is accelerating, stabilizing, or decelerating. The earnings calendar on Smart Investors Daily tracks upcoming report dates across all publicly traded companies.